- Pharmaceutical companies
- Novo Nordisk
Novo Nordisk
Phone: +355 4 225 3522
Fax: +355 4 2253 554
E-mail: infoal@novonordisk.com
Web: https://www.novonordisk.al
Type | Aktieselskab |
---|---|
Traded as | |
Industry | Pharmaceuticals, Health care |
Founded | December 21, 1923 (1923-12-21) |
Headquarters | Novo Allé, DK-2880, Bagsværd, Denmark |
Key people | Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO) |
Products | Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda |
Revenue | 140.8 billion kr. (2021) |
Operating income | 58.64 billion kr. (2021) |
Net income | 47.76 billion kr. (2021) |
Total assets | 194.5 billion kr. (2021) |
Total equity | 70.75 billion kr. (2021) |
Number of employees | 48,478 (end 2021) |
Website | novonordisk.com |
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 43,000 people in 80 offices around the world, and market our products in 170 countries.
For detailed contact information visit location pages below.
Novo Nordisk's locations around the world
Europe
North America
Asia
Africa
Oceania
Clinical Trials sponsored by Novo Nordisk
-
Novo Nordisk A/SNot yet recruiting
-
Novo Nordisk A/SRecruitingHealthy Volunteers | Cardiometabolic DiseasesNetherlands
-
Novo Nordisk A/SRecruitingType 2 DiabetesUnited States, Serbia, Italy, Poland, China, Hungary, Saudi Arabia
-
Novo Nordisk A/SNot yet recruiting
-
Novo Nordisk A/SRecruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
-
Novo Nordisk A/SRecruitingType 2 DiabetesUnited States, Taiwan, Australia, Hungary, Germany, India, Canada, Spain, Czechia, Argentina, Poland, Colombia, South Africa, France, Greece, Romania
-
Novo Nordisk A/SRecruitingHeart Failure | Systemic InflammationUnited States, Greece, France, Australia, Czechia, Spain, India, Canada, Turkey, Portugal, Malaysia, Poland, United Kingdom, Germany, Bulgaria, Argentina
-
Novo Nordisk A/SRecruitingObesity | Type 2 Diabetes | Chronic Kidney DiseaseUnited States, Spain, Thailand, India, France, Poland, Canada, Japan, Greece, Hungary, Argentina, Brazil, Slovakia
-
Novo Nordisk A/SRecruiting
-
Novo Nordisk A/SNot yet recruiting